Advice
In the absence of a submission from the holder of the marketing authorisation.
Rivastigmine (Exelon) is not recommended for use within NHS Scotland for the treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- rivastigmine (Exelon)
- SMC ID:
- 310/06
- Indication:
- Mild to moderately severe dementia in patients with idiopathic Parkinson' s disease
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 August 2006